Humanetics Corp.

Humanetics Corp. is a clinical-stage biotech focused on improving outcomes in solid tumor cancers and radiation-related injuries through its lead drug candidate, BIO 300. The company is advancing BIO 300 across three core areas: oncology (as a radioprotector/radiosensitizer), inflammatory lung diseases (e.g., post-COVID fibrosis), and biodefense (as a medical countermeasure for acute radiation syndrome). With strong backing from U.S. federal agencies like the DoD and a pipeline in Phase 2 development, Humanetics is positioning its platform technology to address significant unmet needs in both civilian and government markets.

Radiation modulators; small molecule drugs (e.g., BIO 300 nanosuspension) that selectively modulate the body's response to radiation and inflammation, primarily via the Nrf2 pathway, to protect healthy tissue and sensitize tumors.

In oncology radioprotection, competition includes agents like amifostine (limited by toxicity), creating an opening for a safer, more effective option. In anti-fibrotic lung disease, BIO 300 would compete with approved drugs like pirfenidone and nintedanib. In the biodefense radiation countermeasure space, the competitive field is narrower, but approval requires navigating a unique regulatory and procurement landscape dominated by government contracts.